Additionally, Leung reported that resistance to sorafenib in HCC could be influenced by nuclear factor (erythroid-derived 2)-like 2 (NRF2), which is known to bind to the promoter of the SHH gene [54]. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.